Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents

Zheng Rong Lu, Aaron M Mohs, Yuda Zong, Yi Feng

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR) cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety concerns related to these agents' slow elimination from the body impede their clinical development. Polydisulfide Gd(III) complexes have been designed and developed as biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as low-molecular-weight agents. The rationale and recent development of the novel biodegradable contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue retention as the clinically used low-molecular-weight agents. Structural modification of the agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes are promising for further clinical development as safe, effective, biodegradable macromolecular MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic response.

Original languageEnglish (US)
Pages (from-to)31-40
Number of pages10
JournalInternational journal of nanomedicine
Volume1
Issue number1
DOIs
StatePublished - Dec 1 2006

Fingerprint

Gadolinium
Magnetic resonance
Contrast Media
Magnetic Resonance Imaging
Imaging techniques
Blood Circulation Time
Tumors
Hemodynamics
Neoplasms
Animals
Animal Models
Molecular Weight
Molecular weight
Tissue
Vascular Tissue Neoplasms
Blood vessels
Blood
Kidney
Safety
Kinetics

Keywords

  • Biodegradable
  • Contrast agents
  • Gadolinium
  • MRI
  • Polydisulfide

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Drug Discovery
  • Organic Chemistry

Cite this

Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. / Lu, Zheng Rong; Mohs, Aaron M; Zong, Yuda; Feng, Yi.

In: International journal of nanomedicine, Vol. 1, No. 1, 01.12.2006, p. 31-40.

Research output: Contribution to journalReview article

@article{fca4f3eb92a24c638403dcc5352bf518,
title = "Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents",
abstract = "Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR) cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety concerns related to these agents' slow elimination from the body impede their clinical development. Polydisulfide Gd(III) complexes have been designed and developed as biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as low-molecular-weight agents. The rationale and recent development of the novel biodegradable contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue retention as the clinically used low-molecular-weight agents. Structural modification of the agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes are promising for further clinical development as safe, effective, biodegradable macromolecular MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic response.",
keywords = "Biodegradable, Contrast agents, Gadolinium, MRI, Polydisulfide",
author = "Lu, {Zheng Rong} and Mohs, {Aaron M} and Yuda Zong and Yi Feng",
year = "2006",
month = "12",
day = "1",
doi = "10.2147/nano.2006.1.1.31",
language = "English (US)",
volume = "1",
pages = "31--40",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents

AU - Lu, Zheng Rong

AU - Mohs, Aaron M

AU - Zong, Yuda

AU - Feng, Yi

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR) cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety concerns related to these agents' slow elimination from the body impede their clinical development. Polydisulfide Gd(III) complexes have been designed and developed as biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as low-molecular-weight agents. The rationale and recent development of the novel biodegradable contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue retention as the clinically used low-molecular-weight agents. Structural modification of the agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes are promising for further clinical development as safe, effective, biodegradable macromolecular MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic response.

AB - Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR) cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety concerns related to these agents' slow elimination from the body impede their clinical development. Polydisulfide Gd(III) complexes have been designed and developed as biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as low-molecular-weight agents. The rationale and recent development of the novel biodegradable contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue retention as the clinically used low-molecular-weight agents. Structural modification of the agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes are promising for further clinical development as safe, effective, biodegradable macromolecular MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic response.

KW - Biodegradable

KW - Contrast agents

KW - Gadolinium

KW - MRI

KW - Polydisulfide

UR - http://www.scopus.com/inward/record.url?scp=33746910245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746910245&partnerID=8YFLogxK

U2 - 10.2147/nano.2006.1.1.31

DO - 10.2147/nano.2006.1.1.31

M3 - Review article

VL - 1

SP - 31

EP - 40

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

IS - 1

ER -